5 Stocks to Watch: Week of 4/6/2026

Here’s a list that’s better than a golden egg: 5 high-potential stocks to watch in the coming week, including:

• Micron Technology (MU) — #1 semiconductor stock with 64% EPS growth ahead
• Ciena Corp (CIEN) — AI networking backbone with 716% surge from lows
• Tenet Healthcare (THC) — 15 analysts agree: this healthcare giant is a Strong Buy
• Nature's Sunshine Products (NATR) — Record-breaking results from the #1 Zen Rated stock
• AnaptysBio (ANAB) — Major spin-off and $100M buyback fuel analyst excitement

Let's get to it.

A note from our sponsors...

1- Tenet Healthcare Corp (NYSE: THC)

With earnings momentum building ahead of its May 5th report, diversified healthcare player THC is turning heads on Wall Street as one of the highest-rated stocks in the A-rated Medical Care Facility industry.

Zen Rating: Strong Buy (A) — see full analysis

Recent Price: $188.17 — get current quote

Max 1-year forecast: $288.00

Why we're watching:

• Analyst support: THC commands strong Street backing among the analysts we track, with 12 Strong Buy and 3 Buy ratings from 15 analysts. See the ratings
• Truist Securities' David S Macdonald (a top 11% rated analyst) maintains his Strong Buy rating following meetings with management, emphasizing the company's strong fundamentals and positive growth prospects in the healthcare sector.
• UBS analyst A.J. Rice (top 12%) continues to highlight the company's strong demand for healthcare services and expansion plans in underserved markets, supporting the bullish thesis.
• Industry ranking context: THC is currently the 6th highest-rated stock out of 39 in the Medical Care Facility industry, which has an Industry Rating of A.
• Zen Rating highlights: As a Strong Buy (A) rated stock, THC ranks in the top 5% of stocks we track — a category that has historically delivered 32.52% annual returns. 
• Component Grades: The stock earns its strongest marks in Value, Sentiment, and Safety — signaling a favorable risk-reward profile backed by positive analyst outlook. Meanwhile, Growth, Momentum, Financials, and AI scores leave room for upside as the company heads into its next earnings cycle. (See all 7 Zen Component Grades here)

A note from our sponsors...

2- Ciena Corp (NYSE: CIEN)

Ciena is an under-the-radar company wiring the AI revolution. As hyperscalers race to expand data center capacity, Ciena's optical networking has become mission-critical — with cloud provider revenue surging 76% year-over-year and now making up 42% of total sales.

Zen Rating: B (Buy) — see full analysis

Recent Price: $450.00 — get current quote

Max 1-year forecast: $430.00

Why we're watching:

• Analyst support: CIEN currently enjoys 8 Strong Buy ratings, 1 Buy rating, and 4 Hold ratings among 13 analysts we track. See the ratings
• Looking on the bullish side, Stifel Nicolaus' Ruben Roy (a top 1% rated analyst) maintains his Strong Buy rating with a $430 price target (nearly 20% upside) following Ciena's very strong fiscal first quarter results, noting unprecedented, broad-based demand as the company enables customers to monetize their AI investments.
• Recently, Ciena delivered exceptional Q1 2026 results with EPS of $1.35 (beating estimates of $1.14) and revenue of $1.43B, issuing full-year guidance of $5.9B to $6.3B as management noted industry-leading technology and deep customer relationships position them well for multi-year AI-driven demand.
• Industry ranking context: CIEN is currently the 8th highest-rated stock in the Communication Equipment industry, which has an Industry Rating of B. See more winning picks in the industry here.
• Zen Rating highlights: With its B rating, CIEN has demonstrated exceptional potential based on our 115-factor review, and lands in a class of stocks that have historically delivered nearly 20% annually to investors.
• Component Grades: Looking at the Component Grades that shape the overall rating, Ciena shows excellent strength with A and B grades across Growth, Momentum, Sentiment, Safety, and Financials. See all 7 Zen Component Grades here

3- AnaptysBio Inc (NASDAQ: ANAB)

With the First Tracks Biotherapeutics spin-off set for April 20th and a freshly authorized $100 million stock repurchase plan, this biotech company is entering a transformative stretch that has Wall Street paying close attention.

Zen Rating: Buy (B) — see full analysis

Recent Price: $57.69 — get current quote

Max 1-year forecast: $100.00

Why we're watching:

• Analyst support: ANAB commands strong backing with 6 Strong Buy and 2 Buy ratings from 8 covering analysts. See the ratings
• For instance, Barclays analyst Etzer Darout (a top 2% rated analyst) maintains his Strong Buy rating with a $79 price target (40%+ upside), believing that AnaptysBio's innovative approaches will drive success in an evolving market, emphasizing that competitive advantages are growing.
• Guggenheim's Yatin Suneja (top 3%) sets the Street-high $100 price target (+80.31% upside), with insights suggesting a bullish future based on data from recent trials showing that innovations are driving growth and data supports potential market share gains. 
• Industry ranking context: ANAB is currently the 16th highest-rated stock in the Biotech industry. See all biotech stocks here.
• Zen Rating highlights: ANAB currently earns a Zen Rating of B (Buy), which means it ranks in the top 20% of stocks we track based on a careful 115-factor review. Considering the volatility of the biotech industry, this is pretty impressive.
• Component Grades: ANAB demonstrates balanced strength with a Momentum grade of B, though the Safety grade of F reflects the typical risk profile of clinical-stage biotech companies, while Financials earn a B grade supported by a strong 45.8% profit margin. (See all 7 Zen Component Grades here)

4- Micron Technology (NASDAQ: MU)

Micron Technology is the memory powerhouse fueling the AI revolution — now mass-producing its next-gen HBM4 memory for Nvidia's Vera Rubin platform amid an industry-wide chip shortage that analysts say could last through 2030. With revenue nearly tripling year-over-year, this isn't just a cyclical chip stock — it's a structural AI play.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $364.67 — get current quote

Max 1-year forecast: $700.00

Why we're watching:

• Analyst support: Overwhelming confidence with 17 Strong Buy ratings, 7 Buy ratings, and just 1 Hold among 25 analysts covering the stock. See the ratings
• Mizuho's Vijay Rakesh (a top 1% rated analyst) maintains his Buy rating with a $530 price target (46.88% upside) following Micron's memory recovery from previous pricing pressures.
• JP Morgan's Harlan Sur (top 2%) maintains his Strong Buy rating with a $550 price target (62.80% upside) citing Micron's focus on DRAM and NAND technology positioning it well in a booming semiconductor market driven by data center applications and AI landscape demands.
• This is another valued stock pick in our Zen Investor portfolio — it was also recently featured as a top alternative to Nvidia in this video.
• Industry ranking context: MU is currently the #1 highest-rated stock in the Semiconductor industry, which has an Industry Rating of B.
• Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr — Micron ranks as the top semiconductor stock among 65 companies tracked in its sector.
• Component Grades: Micron excels with A grades in Value, Growth, Financials, and Sentiment, reflecting its exceptional market position with a 57.8% profit margin and projected EPS growth of 64% year-over-year, though Safety earns a D grade due to its high beta of 1.77. See all 7 Zen Component Grades here

A note from our sponsors...

5- Natures Sunshine Products (NASDAQ: NATR)

Despite operating in a challenging D-rated Food industry, natural food and wellness company NATR shines as the 2nd highest-rated stock in the sector — backed by record-breaking results and unanimous Strong Buy ratings from covering analysts.

Zen Rating: Strong Buy (A) — see full analysis

Recent Price: $24.25 — get current quote

Max 1-year forecast: $33.00

Why we're watching:

• Analyst support: NATR enjoys unanimous support and Strong Buy ratings among the analysts we track issuing ratings. See the ratings
• For example, Canaccord Genuity's Susan Anderson (a top 13% rated analyst) maintains her Strong Buy rating and projected 37% upside price target, highlighting NATR's potential to outperform the industry due to its unique positioning and branding strategy, with strategic partnerships expected to enhance distribution. 
• NATR is a valued addition to our Zen Investor portfolio, where Editor-in-Chief Steve Reitmeister rates the stock a Buy and praises its solid fundamentals and excellent historical track record. 
• The company's earnings report beat revenue estimates by 7.76% with year-over-year revenue growth of 7.76%, while management remains optimistic about upcoming trends in health and wellness that may favor their product line.
• Industry ranking context: NATR is currently the 2nd highest-rated stock in the Food industry, though as previously noted, the industry is not well-rated. (Here’s why Industry Ranking matters.)
• Zen Rating highlights: NATR ranks in the top 1% of stocks we track based on fundamentals — a fact that shouldn’t be ignored despite the ailing industry. Its overall rating is A (Strong Buy).
• Component Grades: Sentiment earns an excellent A grade, while Value and Financials earn above-average Bs. (See all 7 Zen Component Grades here)

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.